{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T07:05:15Z","timestamp":1779779115445,"version":"3.53.1"},"reference-count":33,"publisher":"Walter de Gruyter GmbH","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_med-2026-1422_abs_001\">\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Bioinformatics analysis suggests that the A-Raf proto-oncogene serine\/threonine kinase (ARAF) is closely associated with bladder cancer and the mitogen-activated protein kinase (MAPK) pathway. In this study, we aimed to investigate the role and molecular mechanisms of ARAF in bladder cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_med-2026-1422_abs_002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Genes associated with bladder cancer were analyzed using public databases, and KEGG analysis was performed. ARAF expression in bladder cancer cells was assessed using RT-qPCR and western blotting. Cell proliferation and apoptosis were measured using EdU fluorescence and flow cytometry, respectively. Cell migration and invasion were detected using Transwell assays. EMT-related and p38MAPK pathway proteins were analyzed through western blotting. Finally, the p38 MAPK pathway activator, anisomycin, was used to explore the mechanism of ARAF in cancer\u00a0cells.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_med-2026-1422_abs_003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Intersecting genes related to bladder cancer were identified from the GeneCards and CTD databases, and ARAF was enriched in the p38MAPK pathway. ARAF expression was elevated in cancer cells, and its inhibition significantly reduced cell proliferation and metastasis, promoted cell apoptosis, and suppressed p38MAPK pathway activation. Anisomycin reversed the inhibitory effects of si-ARAF on T24\u00a0cells.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_med-2026-1422_abs_004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Inhibition of ARAF suppresses malignant proliferation and metastasis of bladder cancer cells by repressing the p38MAPK pathway.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/med-2026-1422","type":"journal-article","created":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T06:57:13Z","timestamp":1779778633000},"source":"Crossref","is-referenced-by-count":0,"title":["ARAF regulates malignant progression of bladder cancer through the p38MAPK pathway"],"prefix":"10.1515","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-6843-7811","authenticated-orcid":false,"given":"Xian","family":"Zhao","sequence":"first","affiliation":[{"name":"Department of Urology , Taikang Tongji (Wuhan) Hospital , Wuhan , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9631-7843","authenticated-orcid":false,"given":"Xiaojing","family":"Xu","sequence":"additional","affiliation":[{"name":"Health Care Office, Wuhan No. 1 Hospital (Wuhan Hospital of Traditional Chinese and Western Medicine) , Wuhan , China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2026,5,26]]},"reference":[{"key":"2026052606570863649_j_med-2026-1422_ref_001","doi-asserted-by":"crossref","unstructured":"Comp\u00e9rat, E, Amin, MB, Cathomas, R, Choudhury, A, De Santis, M, Kamat, A, et al.. Current best practice for bladder cancer: a narrative review of diagnostics and treatments. Lancet 2022;400:1712\u201321. https:\/\/doi.org\/10.1016\/S0140-6736(22)01188-6.","DOI":"10.1016\/S0140-6736(22)01188-6"},{"key":"2026052606570863649_j_med-2026-1422_ref_002","doi-asserted-by":"crossref","unstructured":"Ahmadi, H, Duddalwar, V, Daneshmand, S. Diagnosis and staging of bladder cancer. Hematol Oncol Clin N Am 2021;35:531\u201341. https:\/\/doi.org\/10.1016\/j.hoc.2021.02.004.","DOI":"10.1016\/j.hoc.2021.02.004"},{"key":"2026052606570863649_j_med-2026-1422_ref_003","doi-asserted-by":"crossref","unstructured":"Dyrskj\u00f8t, L, Hansel, DE, Efstathiou, JA, Knowles, MA, Galsky, MD, Teoh, J, et al.. Bladder cancer. Nat Rev Dis Primers 2023;9:58. https:\/\/doi.org\/10.1038\/s41572-023-00468-9. Published 2023 Oct 26.","DOI":"10.1038\/s41572-023-00468-9"},{"key":"2026052606570863649_j_med-2026-1422_ref_004","doi-asserted-by":"crossref","unstructured":"Lobo, N, Afferi, L, Moschini, M, Mostafid, H, Porten, S, Psutka, SP, et al.. Epidemiology, screening, and prevention of bladder cancer. Eur Urol Oncol 2022;5:628\u201339. https:\/\/doi.org\/10.1016\/j.euo.2022.10.003.","DOI":"10.1016\/j.euo.2022.10.003"},{"key":"2026052606570863649_j_med-2026-1422_ref_005","doi-asserted-by":"crossref","unstructured":"Jubber, I, Ong, S, Bukavina, L, Black, PC, Comp\u00e9rat, E, Kamat, AM, et al.. Epidemiology of bladder cancer in 2023: a systematic review of risk factors. Eur Urol 2023;84:176\u201390. https:\/\/doi.org\/10.1016\/j.eururo.2023.03.029.","DOI":"10.1016\/j.eururo.2023.03.029"},{"key":"2026052606570863649_j_med-2026-1422_ref_006","doi-asserted-by":"crossref","unstructured":"Liu, L, Xu, L, Wu, D, Zhu, Y, Li, X, Xu, C, et al.. Impact of tumour stroma-immune interactions on survival prognosis and response to neoadjuvant chemotherapy in bladder cancer. EBioMedicine 2024;104:105152. https:\/\/doi.org\/10.1016\/j.ebiom.2024.105152.","DOI":"10.1016\/j.ebiom.2024.105152"},{"key":"2026052606570863649_j_med-2026-1422_ref_007","doi-asserted-by":"crossref","unstructured":"ARAF mutations limit response to RAF dimer inhibition. Cancer Discov. 2021;11:1610. https:\/\/doi.org\/10.1158\/2159-8290.CD-RW2021-069.","DOI":"10.1158\/2159-8290.CD-RW2021-069"},{"key":"2026052606570863649_j_med-2026-1422_ref_008","doi-asserted-by":"crossref","unstructured":"Su, W, Mukherjee, R, Yaeger, R, Son, J, Xu, J, Na, N, et al.. ARAF protein kinase activates RAS by antagonizing its binding to RASGAP NF1. Mol Cell 2022;82:2443\u201357.e7. https:\/\/doi.org\/10.1016\/j.molcel.2022.04.034.","DOI":"10.1016\/j.molcel.2022.04.034"},{"key":"2026052606570863649_j_med-2026-1422_ref_009","doi-asserted-by":"crossref","unstructured":"Venkatanarayan, A, Liang, J, Yen, I, Shanahan, F, Haley, B, Phu, L, et al.. CRAF dimerization with ARAF regulates KRAS-driven tumor growth. Cell Rep 2022;38:110351. https:\/\/doi.org\/10.1016\/j.celrep.2022.110351.","DOI":"10.1016\/j.celrep.2022.110351"},{"key":"2026052606570863649_j_med-2026-1422_ref_010","doi-asserted-by":"crossref","unstructured":"Mooz, J, Riegel, K, Ps, H, Sadanandam, A, Marini, F, Klein, M, et al.. ARAF suppresses ERBB3 expression and metastasis in a subset of lung cancers. Sci Adv 2022;8:eabk1538. https:\/\/doi.org\/10.1126\/sciadv.abk1538.","DOI":"10.1126\/sciadv.abk1538"},{"key":"2026052606570863649_j_med-2026-1422_ref_011","doi-asserted-by":"crossref","unstructured":"Lin, W, Tong, C, Zhang, W, Cen, W, Wang, Y, Li, J, et al.. Silencing ARAF suppresses the malignant phenotypes of gallbladder cancer cells. Biomed Res Int 2020;2020:3235786. https:\/\/doi.org\/10.1155\/2020\/3235786.","DOI":"10.1155\/2020\/3235786"},{"key":"2026052606570863649_j_med-2026-1422_ref_012","doi-asserted-by":"crossref","unstructured":"Sia, D, Losic, B, Moeini, A, Cabellos, L, Hao, K, Revill, K, et al.. Massive parallel sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma. Nat Commun 2015;6:6087. https:\/\/doi.org\/10.1038\/ncomms7087.","DOI":"10.1038\/ncomms7087"},{"key":"2026052606570863649_j_med-2026-1422_ref_013","doi-asserted-by":"crossref","unstructured":"Kameyama, K, Mizutani, K, Yamada, T, Sugiyama, S, Kamei, S, Yokoi, S, et al.. Genomic analysis of bladder urothelial carcinoma with osteoclast-like giant cells: a case report. Mol Clin Oncol 2024;21:55. https:\/\/doi.org\/10.3892\/mco.2024.2753.","DOI":"10.3892\/mco.2024.2753"},{"key":"2026052606570863649_j_med-2026-1422_ref_014","doi-asserted-by":"crossref","unstructured":"Wagner, EF, Nebreda, AR. Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer 2009;9:537\u201349. https:\/\/doi.org\/10.1038\/nrc2694.","DOI":"10.1038\/nrc2694"},{"key":"2026052606570863649_j_med-2026-1422_ref_015","doi-asserted-by":"crossref","unstructured":"He, D, Wu, H, Xiang, J, Ruan, X, Peng, P, Ruan, Y, et al.. Gut stem cell aging is driven by mTORC1 via a p38\u00a0MAPK-p53 pathway. Nat Commun 2020;11:37. https:\/\/doi.org\/10.1038\/s41467-019-13911-x.","DOI":"10.1038\/s41467-019-13911-x"},{"key":"2026052606570863649_j_med-2026-1422_ref_016","doi-asserted-by":"crossref","unstructured":"Coulthard, LR, White, DE, Jones, DL, McDermott, MF, Burchill, SA. p38(MAPK): stress responses from molecular mechanisms to therapeutics. Trends Mol Med 2009;15:369\u201379. https:\/\/doi.org\/10.1016\/j.molmed.2009.06.005.","DOI":"10.1016\/j.molmed.2009.06.005"},{"key":"2026052606570863649_j_med-2026-1422_ref_017","doi-asserted-by":"crossref","unstructured":"Cheng, Y, Sun, F, Wang, L, Gao, M, Xie, Y, Sun, Y, et al.. Virus-induced p38 MAPK activation facilitates viral infection. Theranostics 2020;10:12223\u201340. https:\/\/doi.org\/10.7150\/thno.50992.","DOI":"10.7150\/thno.50992"},{"key":"2026052606570863649_j_med-2026-1422_ref_018","doi-asserted-by":"crossref","unstructured":"Yan, W, Wang, X, Wang, W, Guo, Q, Huang, N, Chen, H, et al.. The p38\/MAPK pathway as a therapeutic target to prevent therapeutic escape of breast cancer stem cells. Sci China Life Sci 2024;67:1867\u201380. https:\/\/doi.org\/10.1007\/s11427-023-2585-5.","DOI":"10.1007\/s11427-023-2585-5"},{"key":"2026052606570863649_j_med-2026-1422_ref_019","doi-asserted-by":"crossref","unstructured":"Xiong, L, Guo, W, Yang, Y, Gao, D, Wang, J, Qu, Y, et al.. Tectoridin inhibits the progression of colon cancer through downregulating PKC\/p38 MAPK pathway. Mol Cell Biochem 2021;476:2729\u201338. https:\/\/doi.org\/10.1007\/s11010-021-04081-w.","DOI":"10.1007\/s11010-021-04081-w"},{"key":"2026052606570863649_j_med-2026-1422_ref_020","doi-asserted-by":"crossref","unstructured":"Zou, F, Rao, T, Chen, W, Song, T, Li, T, Hu, W, et al.. DUSP2 affects bladder cancer prognosis by down-regulating MEK\/ERK and P38 MAPK\u00a0signaling pathways through PTPN7. Cell Signal 2023;112:110893. https:\/\/doi.org\/10.1016\/j.cellsig.2023.110893.","DOI":"10.1016\/j.cellsig.2023.110893"},{"key":"2026052606570863649_j_med-2026-1422_ref_021","doi-asserted-by":"crossref","unstructured":"Yang, L, Huang, W, Bai, X, Wang, H, Wang, X, Xiao, H, et al.. Androgen dihydrotestosterone promotes bladder cancer cell proliferation and invasion via EPPK1-mediated MAPK\/JUP signaling. Cell Death Dis 2023;14:363. https:\/\/doi.org\/10.1038\/s41419-023-05882-1.","DOI":"10.1038\/s41419-023-05882-1"},{"key":"2026052606570863649_j_med-2026-1422_ref_022","doi-asserted-by":"crossref","unstructured":"Chen, YR, Wang, SC, Huang, SP, Su, CC, Liu, PL, Cheng, WC, et al.. Protodioscin inhibits bladder cancer cell migration and growth, and promotes apoptosis through activating JNK and p38 signaling pathways. Biomed Pharmacother 2022;156:113929. https:\/\/doi.org\/10.1016\/j.biopha.2022.113929.","DOI":"10.1016\/j.biopha.2022.113929"},{"key":"2026052606570863649_j_med-2026-1422_ref_023","doi-asserted-by":"crossref","unstructured":"Chen, W, Yang, W, Zhang, C, Liu, T, Zhu, J, Wang, H, et al.. Modulation of the p38 MAPK pathway by anisomycin promotes ferroptosis of hepatocellular carcinoma through phosphorylation of H3S10. Oxid Med Cell Longev. 2022;2022:6986445. https:\/\/doi.org\/10.1155\/2022\/6986445.","DOI":"10.1155\/2022\/6986445"},{"key":"2026052606570863649_j_med-2026-1422_ref_024","doi-asserted-by":"crossref","unstructured":"Jin, YH, Zeng, XT, Liu, TZ, Bai, ZM, Dou, ZL, Ding, DG, et al.. Treatment and surveillance for non-muscle-invasive bladder cancer: a clinical practice guideline (2021 edition). Milit Med Res 2022;9:44. https:\/\/doi.org\/10.1186\/s40779-022-00406-y.","DOI":"10.1186\/s40779-022-00406-y"},{"key":"2026052606570863649_j_med-2026-1422_ref_025","doi-asserted-by":"crossref","unstructured":"Mertens, LS, Psutka, SP, Mir, MC. Bladder cancer oligometastases - definition and treatment. Nat Rev Urol 2023;20:701\u20132. https:\/\/doi.org\/10.1038\/s41585-023-00815-1.","DOI":"10.1038\/s41585-023-00815-1"},{"key":"2026052606570863649_j_med-2026-1422_ref_026","doi-asserted-by":"crossref","unstructured":"Guerrero-Ramos, F, Boormans, JL, Daneshmand, S, Gontero, P, Kamat, AM, Roupr\u00eat, M, et al.. Novel delivery systems and pharmacotherapeutic approaches for the treatment of non-muscle-invasive bladder cancer. Eur Urol Oncol 2024;7:1267\u201379. https:\/\/doi.org\/10.1016\/j.euo.2024.05.012.","DOI":"10.1016\/j.euo.2024.05.012"},{"key":"2026052606570863649_j_med-2026-1422_ref_027","doi-asserted-by":"crossref","unstructured":"Al Hussein Al Awamlh, B, Chang, SS. Novel therapies for high-risk non-muscle invasive bladder cancer. Curr Oncol Rep 2023;25:83\u201391. https:\/\/doi.org\/10.1007\/s11912-022-01350-9.","DOI":"10.1007\/s11912-022-01350-9"},{"key":"2026052606570863649_j_med-2026-1422_ref_028","doi-asserted-by":"crossref","unstructured":"Kimura, K, Yoshida, S, Tsuchiya, J, Kitazume, Y, Waseda, Y, Tanaka, H, et al.. Novel utility of vesical imaging-reporting and data system in multimodal treatment for muscle-invasive bladder cancer. Eur Radiol 2023;33:6245\u201355. https:\/\/doi.org\/10.1007\/s00330-023-09627-8.","DOI":"10.1007\/s00330-023-09627-8"},{"key":"2026052606570863649_j_med-2026-1422_ref_029","unstructured":"Li, M, Zhang, N, Shan, W, Guan, B. ALG3 is a potential biomarker for the prognosis of bladder cancer. Ann Clin Lab Sci 2022;52:117\u201325."},{"key":"2026052606570863649_j_med-2026-1422_ref_030","doi-asserted-by":"crossref","unstructured":"Hu, WM, Li, M, Ning, JZ, Tang, YQ, Song, TB, Li, LZ, et al.. FAM171B stabilizes vimentin and enhances CCL2-mediated TAM infiltration to promote bladder cancer progression. J\u00a0Exp Clin Cancer Res 2023;42:290. https:\/\/doi.org\/10.1186\/s13046-023-02860-5.","DOI":"10.1186\/s13046-023-02860-5"},{"key":"2026052606570863649_j_med-2026-1422_ref_031","doi-asserted-by":"crossref","unstructured":"Sarg, NH, Zaher, DM, Abu Jayab, NN, Mostafa, SH, Ismail, HH, Omar, HA. The interplay of p38 MAPK signaling and mitochondrial metabolism, a dynamic target in cancer and pathological contexts. Biochem Pharmacol 2024;225:116307. https:\/\/doi.org\/10.1016\/j.bcp.2024.116307.","DOI":"10.1016\/j.bcp.2024.116307"},{"key":"2026052606570863649_j_med-2026-1422_ref_032","doi-asserted-by":"crossref","unstructured":"Thi, TN, Thanh, HD, Nguyen, VT, Kwon, SY, Moon, C, Hwang, EC, et al.. Complement regulatory protein CD46 promotes bladder cancer metastasis through activation of MMP9. Int J Oncol 2024;65:71. https:\/\/doi.org\/10.3892\/ijo.2024.5659.","DOI":"10.3892\/ijo.2024.5659"},{"key":"2026052606570863649_j_med-2026-1422_ref_033","doi-asserted-by":"crossref","unstructured":"Zhi, Y, Cai, C, Xu, T, Sun, F, Wang, KP, Ji, Z, et al.. Silencing of FGF6 hampers aerobic glycolysis and angiogenesis in bladder cancer by regulating PI3K\/Akt and MAPK signaling pathways. J\u00a0Biochem Mol Toxicol 2023;37:e23399. https:\/\/doi.org\/10.1002\/jbt.23399.","DOI":"10.1002\/jbt.23399"}],"container-title":["Open Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/med-2026-1422\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/med-2026-1422\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T06:57:31Z","timestamp":1779778651000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/med-2026-1422\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,1]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,5,26]]},"published-print":{"date-parts":[[2026,1,23]]}},"alternative-id":["10.1515\/med-2026-1422"],"URL":"https:\/\/doi.org\/10.1515\/med-2026-1422","relation":{},"ISSN":["2391-5463"],"issn-type":[{"value":"2391-5463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,1]]},"article-number":"20261422"}}